...year, represents Ipsen’s best near-term growth prospect. However, partner Exelixis Inc....

...the target of which is undisclosed; as well as programs partnered with Sotio a.s. and Exelixis Inc....

...and is eligible for more than $1 billion in milestones, plus royalties. Exelixis in-licenses ADC from Iconic Exelixis Inc....
...cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Biosight Ltd. Exelixis Inc. Iconic...

...Clinical Oncology (ASCO) meeting in May (see “ASCO Data Bring New Markets Within Reach”). BMS and Exelixis Inc....
...Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Bristol-Myers Squibb Co. Exelixis Inc. Immunomedics...

...Alkahest for $37.5 million in cash (see “Age Factors”).Exelixis...
...AG received $25 million up front from Exelixis Inc....
...conjugate (ADC) platform, which uses anthracycline-based payloads. Exelixis...

...a 40% risk reduction on the OS endpoint (HR=0.60; p<0.001). Ipsen Group (Euronext:IPN; Pink:IPSEY) and Exelixis Inc....
...for instance with the European Society of Medical Oncology (ESMO) clinical guideline update in February. Exelixis...
...sales of the drug exceeded $1 billion over a four-quarter period ended Sept. 30, 2019; Exelixis...

...CEO due to personal reasons while remaining chairman. Biogen did not disclose Karp’s next appointment. Exelixis Inc....
...Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo Dainippon Pharma Co. Ltd. Acacia Pharma Group plc Oncopeptides AB Biogen Inc. Exelixis Inc. Unity...

...trial as a monotherapy and a Phase Ib/II study in combination with Cotellic cobimetinib from Exelixis Inc....

...Provenge sipuleucel-T, according to National Comprehensive Cancer Network treatment guidelines (see “Prostate Cancer Disrupted” ). Exelixis Inc....
...cohort that began with 30 patients, but grew to 80 following a July 2019 expansion. Exelixis...
...results from the study have driven Exelixis’ decisions to start pivotal trials in those indications. Exelixis...

...Tecentriq Approval ” and “ Tecentriq First Front-Line SCLC Therapy in Decades ”). Roche and Exelixis Inc....